


Form PTO-1595 (Rev. 03-05)  
 OMB No. 0651-0027 (exp. 6/30/2005)

U.S. DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office

**RECORDATION FORM COVER SHEET  
 PATENTS ONLY**

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

<p><b>1. Name of conveying party(ies):</b>                  Dainippon Sumitomo Pharma Co., Ltd.</p> <p>Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>	<p><b>2. Name and address of receiving party(ies)</b></p> <p>Name: <u>Toshikazu NAKAMURA</u></p> <p>Internal Address: _____</p> <p>Street Address:                  1-4, Hoshojicho, Okazaki                  Sakyo-ku, Kyoto-shi                  Kyoto                  606-8333                  JAPAN</p> <p>City: _____</p> <p>State: _____</p> <p>Country: _____ Zip: _____</p> <p>Additional name(s) &amp; address(es) attached: <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p><b>3. Nature of conveyance/Execution Date(s):</b></p> <p>Execution Date(s): <u>February 28, 2006</u></p> <p><input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Change of Name  <input type="checkbox"/> Security Agreement <input type="checkbox"/> Joint Research Agreement  <input type="checkbox"/> Government Interest Assignment  <input type="checkbox"/> Executive Order 9424, Confirmatory License  <input type="checkbox"/> Other _____</p>	<p><b>4. Application or patent number(s):</b> <input type="checkbox"/> This document is being filed together with a new application.</p> <p>A. Patent Application No.(s)                  11/188,091</p> <p>B. Patent No.(s)</p> <p>Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p><b>5. Name and address to whom correspondence concerning document should be mailed:</b></p> <p>Name: <u>Mark J. Nuell, Ph.D.</u>  <u>BIRCH, STEWART, KOLASCH &amp; BIRCH,</u>  <u>LLP</u></p> <p>Internal Address: <u>Atty. Dkt.: 4373-0114PUS2</u></p> <p>Street Address: <u>8110 Gatehouse Road</u>  <u>Suite 100 East</u>  <u>P.O. Box 747</u></p> <p>City: <u>Falls Church</u></p> <p>State: <u>VA</u> Zip: <u>22040-0747</u></p> <p>Phone Number: <u>(703) 205-8043</u></p> <p>Fax Number: <u>(703) 205-8050</u></p> <p>Email Address: <u>mailroom@bskb.com</u></p>	<p><b>6. Total number of applications and patents involved:</b> <span style="border: 1px solid black; padding: 2px 10px;">1</span></p> <p><b>7. Total fee (37 CFR 1.21(h) &amp; 3.41)</b> \$ <u>40.00</u></p> <p><input type="checkbox"/> Authorized to be charged by credit card  <input checked="" type="checkbox"/> Authorized to be charged to deposit account  <input type="checkbox"/> Enclosed  <input type="checkbox"/> None required (government interest not affecting title)</p>
<p><b>8. Payment Information</b></p> <p>a. Credit Card Last 4 Numbers _____                  Expiration Date _____</p> <p>b. Deposit Account Number <u>02-2448</u>                  Authorized User Name <u>Mark J. Nuell, Ph.D.</u></p>	
<p><b>9. Signature:</b></p> <p style="text-align: center;"></p> <p style="text-align: center;">Signature <span style="float: right;">Date <u>May 16, 2006</u></span></p> <p style="text-align: center;"><u>Mark J. Nuell, Ph.D. - 36,623</u> <span style="float: right;">Total number of pages including cover sheet, attachments, and documents: <span style="border: 1px solid black; padding: 2px 10px;">5</span></span></p> <p style="text-align: center;">Name of Person Signing</p>	

CH \$40.00 022448 11188091

Form PTO-1595	<b>RECORDATION FORM COVER SHEET (continued)</b>
<b>Additional Conveying Party(ies)/Execution Date(s) (1. Continued):</b>	
<b>Additional Assignees (2. Continued):</b>	
Assignee Name: <u>Daiichi Pharmaceutical Co., Ltd.</u>	
Internal Address:	
Street Address: <u>14-10, Nihonbashi 3-chome, Chuo-ku, Tokyo 103-8234 .JAPAN</u>	
City: _____ State: _____ Country: _____ Zip: _____	
Assignee Name: _____	
Internal Address:	
Street Address:	
City: _____ State: _____ Country: _____ Zip: _____	
Assignee Name: _____	
Internal Address:	
Street Address:	
City: _____ State: _____ Country: _____ Zip: _____	
<b>Additional Applications and/or Patents (4. Continued):</b>	
Additional Patent Application Numbers 4A. Continued:	Additional Patent Numbers 4B. Continued:
Additional numbers attached? <input type="checkbox"/> Yes <input type="checkbox"/> No	

Docket No.: 4373-0114PUS2

**ASSIGNMENT**

WHEREAS, Dainippon Sumitomo Pharma Co., Ltd., a corporation organized and existing under and by virtue of the laws of Japan, having an office at 6-8 Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8524 Japan, is the owner by previous assignment of a one-half undivided right, title and interest of Katsumi Tanaka, Kanji Higashio and Eitaro Kumazawa, in and to an invention for new and useful improvements in or relating to Lyophilized HGF Preparations for which an application for Letters Patent in the United States was executed on July 25, 2005, and assigned Application Number 11/188,091;

WHEREAS, Toshikazu Nakamura, a person existing under and by virtue of the laws of Japan, having a residence at 1-4, Hoshojicho, Okazaki, Sakyo-ku, Kyoto-shi, Kyoto 606-8333 Japan; and Daiichi Pharmaceutical Co., Ltd., a corporation organized and existing under and by virtue of the laws of Japan, having an office at 14-10, Nihonbashi 3-chome, Chuo-ku, Tokyo 103-8234 Japan, are desirous of acquiring all right, title and interest held by Dainippon Sumitomo Pharma Co., Ltd. in and to said application and the invention therein described and claimed and any Letters Patent that may be issued upon said application or for the improvements therein contained;

NOW THEREFORE, for and in consideration of the sum of Ten Dollars (\$10.00) lawful money of the United States and other valuable considerations, to me in hand paid, the receipt of and sufficiency whereof are hereby acknowledged, Dainippon Sumitomo Pharma Co., Ltd., has sold, assigned and transferred and does hereby sell, assign and transfer unto Toshikazu Nakamura and Daiichi Pharmaceutical Co., Ltd., their successors and assigns, its entire undivided right, title and interest in and to said application and the invention therein contained, including all rights of action and damages for past infringement, and including the right to apply for any Letters Patent in the United States of America and in all foreign countries on said invention and including the right to claim the priority of the date of filing in the United States and any Letters Patent that may issue thereon, or therefore, in the United States and foreign

Birch, Stewart, Kolasch &amp; Birch, LLP

DRN/CAM/py

countries and all reissues, extensions, renewals, divisions and continuations thereof, to the full end of the term or terms for which said Letters Patent may be issued, to be held and enjoyed by Toshikazu Nakamura and Daiichi Pharmaceutical Co., Ltd., their successors and assigns the same as it would have been held and enjoyed by Dainippon Sumitomo Pharma Co., Ltd., if this assignment and sale had not been made.

AND, Dainippon Sumitomo Pharma Co., Ltd., hereby authorizes and requests the Commissioner of Patents and Trademarks to issue all such Letters Patents to Toshikazu Nakamura and Daiichi Pharmaceutical Co., Ltd., in accordance with this instrument of assignment.

Dainippon Sumitomo Pharma Co., Ltd., hereby represents and warrants that there are no rights or interests outstanding inconsistent with the rights and interests granted herein and that Dainippon Sumitomo Pharma Co., Ltd., will not execute any instrument or grant or transfer any rights or interests inconsistent therewith, and Dainippon Sumitomo Pharma Co., Ltd., binds itself and its heirs, executors, administrators, employees and legal representatives, as the case may be, to execute and deliver to Toshikazu Nakamura and Daiichi Pharmaceutical Co., Ltd., their successors and assigns, any further documents or instruments and do any and all further acts that may be deemed necessary by Toshikazu Nakamura or Daiichi Pharmaceutical Co., Ltd., their successors and assigns to file applications for said improvements and invention in any country where they may elect to file such applications, and that may be necessary to vest in Toshikazu Nakamura and Daiichi Pharmaceutical Co., Ltd., their successors and assigns, the title herein conveyed, or intended so to be, and to enable such title to be recorded in the United States and foreign countries where such application or applications may be filed.


AND, Dainippon Sumitomo Pharma Co., Ltd., further covenants and agrees, in consideration of the premises, that it, its executors and administrators will, at any time upon request, communicate to Toshikazu Nakamura and Daiichi Pharmaceutical Co., Ltd., their successors and assigns, any facts relating to the said invention and improvements and the history thereof, known to it or its successors and assigns, and that it will testify as to the same in any

interference or other proceeding when requested to do so by Toshikazu Nakamura or Daiichi Pharmaceutical Co., Ltd., their successors and assigns.

The undersigned hereby grants the law firm of Birch, Stewart, Kolasch & Birch, LLP the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office for recordation of this document.

IN TESTIMONY WHEREOF, Dainippon Sumitomo Pharma Co., Ltd., has hereunto set its seal this 28<sup>th</sup> day of February, 2006.

Dainippon Sumitomo Pharma Co., Ltd.,

By:   
Kenjiro MIYATAKE  
President

Title: \_\_\_\_\_